At the news
? BEARISHIMPACT 6/10 8-K filed Aug 3, 2026 at 17:06 ET
Stoke Therapeutics filed a prospectus supplement to sell up to $200 million of common stock in an at-the-market (ATM) offering through Cantor Fitzgerald. At a $1.8B market cap, this represents ~11% potential dilution, creating near-term selling pressure and a clear negative signal for existing shareholders.
- On August 3, 2026, Stoke filed a prospectus supplement under its existing Sales Agreement with Cantor Fitzgerald for an ATM offering of up to $200 million in common stock.
- The offering is made under the Company's automatic shelf registration statement on Form S-3ASR (File No. 333-294402) filed March 18, 2026.
- Shares may be sold from time to time at market prices, with no fixed timetable or minimum price.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access